DC Rheum
The Rheumatism Society of the District of Columbia
research

Would you like to submit information about an ongoing or upcoming study? YES

You must have an account and sign in before being able to post a research study. Thanks

 

Research database

The following are current research studies and trials being conducted by members of DC Rheum in the Greater DC Metropolitan area.
If you have posted research that is no longer active, please delete the entry

Research is by grouped disease. Select a from below to jump to that area.

Trial/Study name, sponsor, location Description Contact info
Stopping Anti-TNF Agents in Rheumatoid Arthritis (STARA) Trial Placebo controlled trial of stopping anti-TNF agents in patients with RA with low disease activity/remission (DAS28<2.6). Arthur Weinstein, PI
ACR/REF, MedStar Health Research Institute, NIAMS 202-877-6274
Multi-centered (PA, MD, DC, VA) arthur.weinstein@medstar.net
Submitted: September 7, 2012
Trial/Study name, sponsor, location Description Contact info
JAK-3 for Rheumatoid Arthritis JAK-3 trial for Moderate to Severe Rheumatoid Arthritis subjects who are Methotrexate Inadequate Responders. Subject may be Biologic-naïve or Biologic failures. Kristin Peyton, BS, CCRC
The Center for Rheumatology and Bone Research 301 942-6610
Wheaton, MD kpeyton@arapc.com
Submitted: October 26, 2012
Trial/Study name, sponsor, location Description Contact info
SQ IL-6 for RA SQ human anti-IL-6 monoclonal antibody trial for DMARD failures with active Rheumatoid Arthritis. Jennifer Kalapaca, RN, CCRC
The Center for Rheumatology and Bone Research 301 942-6610
Wheaton, MD tbgoldman@arapc.com
Submitted: March 20, 2013
Trial/Study name, sponsor, location Description Contact info
MabThera vs Rituxan Biosimilar vs Rituxan RA trial for subjects failing anti-TNF agents will receive active treatment without placebo. Sara Hauffe, RN
The Center for Rheumatology and Bone Research 301 942-6610
Wheaton, MD shauffe@arapc.com
Submitted: November 14, 2013
Trial/Study name, sponsor, location Description Contact info
Rheumatoid Arthritis Using H.P. Acthar® Gel Repository Corticotropin Injection As Adjunctive Therapy In Patients With Rheumatoid Arthritis Who Have Failed At Least Three Biologic Therapies With Different Modes Of Action Michelle Grimm
Mallinckrodt Pharmaceuticals 888-717-8839/888-71-
Frederick, MD mgrimm@arthritistreatmentcenter.com
Submitted: April 1, 2015
Trial/Study name, sponsor, location Description Contact info
Jak-1 for RA Jak-1 study for RA subjects who are DMARD inadequate responders. Must be on stable DMARD. If exposed to a biologic, must be less than a 3 month. Megan Bishop BS, CCRC
The Center For Rheumatology and Bone Research 301-942-6610
Wheaton, MD mbishop@arapc.com
Submitted: January 14, 2016
Trial/Study name, sponsor, location Description Contact info
Tofacitinib vs Adalimumab in Subjects with Cardiovascular Risk Factors Subjects greater than 50 yrs in age, currently on MTX with cardiovascular risk factors who have not been exposed to Xeljanz or/and have not failed Humira. Megan Bishop, BS CCRC
The Center for Rheumatology and Bone Research 301-942-6610
Wheaton, MD mbishop@arapc.com
Submitted: January 14, 2016
Trial/Study name, sponsor, location Description Contact info
Withdrawing Etanercept or MTX in subjects with Remission Must be on Enbrel and MTX. 24 week open label with 48 week extension for subjects who are in remission with RA. If disease worsens, subject’s will go back on their original treatment. Ashling Smith
The Center For Rheumatology and Bone Research 301-942-6610
Wheaton, MD asmith@arapc.com
Submitted: January 18, 2016
Trial/Study name, sponsor, location Description Contact info
"Butterfly" Study: Double blind randomized, placebo controlled dose ranging Active SLE - 3 subcutaneous doses of study drug or placebo 8 weeks apart plus 32 weeks follow up. Ike Fleming
Pfizer 202-877-0922
Washington Hospital Center, Arthur Weinstein, PI ike.c.fleming@medstar.net
Submitted: September 7, 2012
Trial/Study name, sponsor, location Description Contact info
Systemic Lupus Erythematosus Placebo-Controlled, Study to Evaluate Efficacy and Safety of a Humanized anti-BAFF IgG-4 SQ Injection in patients with Systemic Lupus Erythematosus with a long term extension Sara Hauffe, RN
The Center for Rheumatology and Bone Research 301 942-6610
Wheaton, MD shauffe@arapc.com
Submitted: March 20, 2013
Trial/Study name, sponsor, location Description Contact info
A Phase 1b, Randomized, Double-Blind, Placebo Controlled Study with an Open A double blind placebo controlled phase 1b trial examining the safety of Omalizumab (anti-IgE antibody) in patients with mild to moderate lupus activity. Elizabeth Joyal, MSN
NIH/NIAMS 301-435-4489
NIH Clinical Center, Bethesda, Md ejoyal@nih.gov
Submitted: May 29, 2015
Trial/Study name, sponsor, location Description Contact info
Studies of the Pathogenesis and the Natural History of Systemic Lupus Eryth Natural History Study open to any individual 10 years old or older who meets the ACR's criteria for lupus. Elizabeth Joyal, MSN
NIH/NIAMS 301-435-4489
Clinical Center, Bethesda, MD ejoyal@nih.gov
Submitted: May 29, 2015
Trial/Study name, sponsor, location Description Contact info
The Role of PPAR-gamma Agonists in imunodulation and Vascular Prevention in Assess the effects of pioglitazone, a PPAR agonist in SLE on vascular function and inflammation and on SLE disease activity. Yenealem Temesgen-Oyelakin, BSN
NIH/NIAMS 301-451-4990
Clinical Center, Bethesda, MD yenealem.temesgen-oyelakin@nih.gov
Submitted: May 29, 2015
Trial/Study name, sponsor, location Description Contact info
XSEL Phase 2 study of XmAB5871 in mod, non-organ threatening SLE. Patients must be willing to come off of DMARDs (other than HCQ and low dose prednisone). Chris Collins
Xencor 202-877-6274
Washington Hospital Center christopher.e.collins@medstar.net
Submitted: July 6, 2016
Trial/Study name, sponsor, location Description Contact info
Fatigability and Cardiorespiratory Fitness in Adolescents and Young Women w Exercise study with emphasis on increasing cardiorespiratory fitness, reducing fatigue, and improving body image in adolescent girls and young women ages 13-25. Liana C. Wooten, DPT
George Mason University 703-772-4510
Fairfax VA lwooten@masonlive.edu
Submitted: February 23, 2017
Trial/Study name, sponsor, location Description Contact info
Scleroderma Lung Study II (SLS II) Double blind study comparing cyclophosphamide to mycophenylate mofetil in interstitial lung disease in scleroderma. Study complete and results will be presented at ATS in May 2015 Aida Manu
NIH 202-444-6211
Georgetown University, Virginia Steen, site PI steenv@georgetown.edu
Submitted: February 5, 2015
Trial/Study name, sponsor, location Description Contact info
IVIG in Refractory Diffuse Scleroderma Controlled trial of severe scleroderma skin (<5 years duration) refractory to celcept or methotrexate. Maia Zulmatashvili
Georgetown University (CSL Behring) 202-444-6210
Georgetown University steenv@georgetown.edu
Submitted: February 5, 2015
Trial/Study name, sponsor, location Description Contact info
Asset Trial (Abatacept in diffuse scleroderma) Double blind, placebo controlled trial for EARLY diffuse scleroderma (can be mild, but less than 2 years of symptoms) Carolyn Fridley
Bristol Myers Squibb 202-444-6211
Georgetown University steenv@georgetown.edu
Submitted: February 5, 2015
Trial/Study name, sponsor, location Description Contact info
RISE SSc (Riociquat in Scleroderma) Double blind placebo controlled using Riociquat (a vasodilatory with anti fibrotic features), in early diffuse scleroderma with less than 2 years of symptoms Maia Zulmatashvili
Bayer Health 202-444-6210
Georgetown University steenv@georgetown.edu
Submitted: February 5, 2015
Trial/Study name, sponsor, location Description Contact info
Tolerization Reduces Intolerance to Pegloticase and Prolongs the Urate Lowe Pegloticase open label study with 8 wks additional dosing extension Megan Bishop BS, CCRC
The Center For Rheumatology and Bone Research 301-942-6610
Wheaton, MD m.bishop@arapc.com
Submitted: January 14, 2016
Trial/Study name, sponsor, location Description Contact info
Tolerization Reduces Intolerance to Pegloticase and Prolongs the Urate Lowe Pegloticase open label study with 8 wks additional dosing extension Megan Bishop BS, CCRC
The Center For Rheumatology and Bone Research 301-942-6610
Wheaton, MD mbishop@arapc.com
Submitted: January 14, 2016
Trial/Study name, sponsor, location Description Contact info
Febuxostat Vs Allopurinol in Subjects with Historyof Cardiovascular Disease Subjects greater than 50 yrs in age with history of cardiovascular disease. Subjects are able to washout of ULT. Sara Hauffe, RN BSN
The Center for Rheumatology and Bone Research 301-942-6610
Wheaton, MD shauffe@arapc.com
Submitted: January 14, 2016
Trial/Study name, sponsor, location Description Contact info
Natural History of Behcet's Disease A natural history study of Behcet's disease in American patients. Patients undergo an extensive clinical evaluation by dermatology, gastroenterology, neurology, ophthalmology, and rheumatology. Serum, blood, RNA, DNA, and tissue samples are collected for research purposes. We are interested in all patients with a diagnosis of Behcet's disease. Cailin Sibley, MD; Elizabeth Joyal, RN
NIH / NIAMS 301-827-4259
Bethesda, MD sibleych@mail.nih.gov
Submitted: September 7, 2012
Trial/Study name, sponsor, location Description Contact info
A Pilot Treatment Study of Anakinra in Behcet's Disease Patients with Behcet's disease and active oral or genital ulcers will be treated with three months of open label anakinra therapy followed by a six month randomized withdrawal. The time to recurrence of ulcers after randomization will be measured as well as an exploratory assessment of biomarkers of disease. Cailin Sibley, MD; Elizabeth Joyal, RN
NIH / NIAMS 301-827-4259
Bethesda, MD sibleych@mail.nih.gov
Submitted: September 7, 2012
Trial/Study name, sponsor, location Description Contact info
Natural History of Systemic Vasculitis We have recently started a translational research program in vasculitis at NIAMS, in affiliation with the Vasculitis Clinical Research Consortium (VCRC). This study is a natural history study of patients with systemic vasculitis. We are interested in all patients with known or suspected small, medium, or large vessel vasculitis. Patients will undergo an extensive clinical evaluation and consultation. DNA, RNA, serum, and tissue will be collected for biomarker discovery programs. Novel imaging protocols will be offered to patients with medium and large vessel vasculitis, including whole body PET-CT, PET-MR, and MRA. Peter Grayson, MD
NIH / NIAMS 301-827-9187
Bethesda, MD peter.grayson@nih.gov
Submitted: November 13, 2013
Trial/Study name, sponsor, location Description Contact info
MYORISK Research study to determine if persons with myositis and the anti-synthetase syndrome (with frequent interstitial lung disease) have experienced different environmental exposures before disease onset compared to other polymyositis/dermatomyositis patients and to healthy individuals. All adult or juvenile polymyositis/dermatomyositis patients diagnosed within the last year are eligible for enrollment. Ms. Tasia Long
NIEHS 301-451-6031
Bethesda, MD longtm@mail.nih.gov
Submitted: September 7, 2012
Trial/Study name, sponsor, location Description Contact info
Erosive Osteoarthrits of the Hand IL-1 SQ injection for subjects with erosive OA of the Hand. 2 year open label trial no placebo Ashling Smith, BA
The Center for Rheumatology and Bone Research 301 942-6610
Wheaton, MD asmith@arapc.com
Submitted: November 14, 2013
Trial/Study name, sponsor, location Description Contact info
Narcotic analogues Comparator trial of Oxycodone vs a new synthetic pain reliever versus placebo. Sara Hauffe, RN
The Center for Rheumatology and Bone Research 301 942-6610
Wheaton, MD shauffe@arapc.com
Submitted: November 14, 2013
Trial/Study name, sponsor, location Description Contact info
OA Viscosupplement Single injection of Hyaluronic Acid vs placebo for subjects with Osteoarthritis of the Knee. Subjects will received open label injection at week 26. Ashling Smith, BA
The Center for Rheumatology and Bone Research 301 942-6610
Wheaton, MD asmith@arapc.com
Submitted: November 14, 2013
Trial/Study name, sponsor, location Description Contact info
Tanezumab Vs NSAIDS for OA of hip or knee 56 week long study of Tanezumab vs. NSAIDs with Tylenol as rescue medication. Subjects must be on stable dose of NSAIDs (naproxen, celebrex or diclofenac) with K-L of greater or equal to 2 at screening. Ashling Smith
The Center For Rheumatology and Bone Research 301-942-6610
Wheaton, MD asmith@arapc.com
Submitted: January 18, 2016
Trial/Study name, sponsor, location Description Contact info
Tanezumab vs Placebo vs Tramadol for Chronic Low Back Pain 56 week long study looking at the efficacy and safety of Tanezumab in subjects with chronic low back pain. Tylenol used for rescue medication. Ashling Smith
The Center For Rheumatology and Bone Research 301-942-6610
Wheaton, MD asmith@arapc.com
Submitted: January 18, 2016
Trial/Study name, sponsor, location Description Contact info
Prospective Longitudinal Observational Study of Fibromyalgia An opportunity for patient to undergo a detailed fibromyalgia evaluation and to be followed every six months. This is being done to see what is the long-term outcomes of fibromyalgia. Patrice Thompson
Georgetown Howard University Centers for Clinical and Translational Researc 202-877-0890
Georgetown University Docwalitt@gmail.com
Submitted: September 7, 2012
Trial/Study name, sponsor, location Description Contact info
Functional MRI in fibromyalgia, osteoarthritis, and pain-free controls A study of the effects of drug withdrawal and exercise therapy on pain and brain function in individuals with fibromyalgia, osteoarthritis, and in pain-free controls. Brian Walitt
American College of Rheumatology 202-549-7669
Georgetown University docwalitt@gmail.com
Submitted: September 7, 2012
Trial/Study name, sponsor, location Description Contact info
Mirogabalin (Next Gen Lyrica) Vs Lyrica Vs Placebo in Subjects with Fibromy Subjects with moderate to severe pain associated with FM. 21 wk study with 52 wk open label. Must be willing to washout of current analgesic management. May stay on SSRIs and Acetaminophen given for breakthrough pain. Ashling Smith, BA
The Center for Rheumatology and Bone Research 301-942-6610
Wheaton, MD asmith@arapc.com
Submitted: January 14, 2016
Trial/Study name, sponsor, location Description Contact info
Siblings discordant for systemic rheumatic disorders NIH is enrolling families in which an adult or child has one of the following: Rheumatoid Arthritis/Juvenile Rheumatoid Arthritis or Systemic Lupus Erythematosus or Systemic Sclerosis or Myositis within 4 years of diagnosis. The study consists of a blood draw, urine collection and completing surveys. Participants must have a sibling of the same gender within 4 years of age without these diseases. Compensation is provided. Call 1-800-411-1222 (TTY: 1-866-411-1010) Refer to study 03-E-0099. The National Institutes of Health is part of the Department of Health and Human Services. Dr. Irene Whitt
NIEHS 301-451-6270
Bethesda, MD irene.whitt@nih.gov
Submitted: September 7, 2012